2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Endocrine
1
Conditions
Neoplasms
2
Pancreatic Neoplasms
1
Neoplasm Metastasis
1
Multiple Endocrine Neoplasia Type 1
1
Lung Cancer Metastatic
1
Hyperlipoproteinemia Type II
1
Glioma
1
Glioblastoma
1
Coronary Disease
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Atherosclerosis
1
Interventions
Fulvestrant
5
Exercise
5
Eating
5
Standard of Care
3
Sodium Chloride
3
Diet
3
Alpelisib
3
ribociclib
2
gallium Ga 68 dotatate
2
exemestane
2
Vitamin D
2
Tamoxifen
2
Magnetic Resonance Spectroscopy
2
Letrozole
2
Ethanol
2
Blood Specimen Collection
2
Anastrozole
2
zopiclone
1
ziprasidone
1
veliparib
1
testosterone undecanoate
1
testosterone enanthate
1
pazopanib
1
mirabegron
1
methyl hydroxyethyl cellulose
1
lenvatinib
1
fluorocholine
1
evolocumab
1
dimethandrolone-undecanoate
1
cyclopropapyrroloindole
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Multiple Endocrine Neoplasia Type 1
×
evolocumab
×
Clear all
NCT03872401
2025-11-10
VESALIUS-CV
Amgen
Phase 3
Completed
12,301 enrolled